Cargando…

A New Era of Therapeutic Strategies for Chronic Thromboembolic Pulmonary Hypertension by Two Different Interventional Therapies; Pulmonary Endarterectomy and Percutaneous Transluminal Pulmonary Angioplasty

BACKGROUND: Pulmonary endarterectomy (PEA) is established for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH). Recently, percutaneous transluminal pulmonary angioplasty (PTPA) has been added for peripheral-type CTEPH, whose lesions exist in segmental, subsegmental, and more di...

Descripción completa

Detalles Bibliográficos
Autores principales: Inami, Takumi, Kataoka, Masaharu, Ando, Motomi, Fukuda, Keiichi, Yoshino, Hideaki, Satoh, Toru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984177/
https://www.ncbi.nlm.nih.gov/pubmed/24728482
http://dx.doi.org/10.1371/journal.pone.0094587
_version_ 1782311413327331328
author Inami, Takumi
Kataoka, Masaharu
Ando, Motomi
Fukuda, Keiichi
Yoshino, Hideaki
Satoh, Toru
author_facet Inami, Takumi
Kataoka, Masaharu
Ando, Motomi
Fukuda, Keiichi
Yoshino, Hideaki
Satoh, Toru
author_sort Inami, Takumi
collection PubMed
description BACKGROUND: Pulmonary endarterectomy (PEA) is established for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH). Recently, percutaneous transluminal pulmonary angioplasty (PTPA) has been added for peripheral-type CTEPH, whose lesions exist in segmental, subsegmental, and more distal pulmonary arteries. A shift in clinical practice of interventional therapies occurred in 2009 (first mainly PEA, later PTPA). We examined the latest clinical outcomes of patients with CTEPH. METHODS AND RESULTS: This study retrospectively included 136 patients with CTEPH. Twenty-nine were treated only with drug (Drug-group), and the other 107 underwent interventional therapies (Interventions-group) (39 underwent PEA [PEA-group] and 68 underwent PTPA [PTPA-group]). Total 213 PTPA sessions (failures, 0%; mortality rate, 1.47%) was performed in the PTPA-group (complications: reperfusion pulmonary edema, 7.0%; hemosputum or hemoptysis, 5.6%; vessel dissection, 2.3%; wiring perforation, 0.9%). Although baseline hemodynamic parameters were significantly more severe in the Interventions-group, the outcome after the diagnosis was much better in the Interventions-group than in the Drug-group (98% vs. 64% 5-year survival, p<0.0001). Hemodynamic improvement in the PEA-group was a 46% decrease in mean pulmonary arterial pressure (PAP) and a 49% decrease in total pulmonary resistance (TPR) (follow-up period; 74.7±32.3 months), while those in the PTPA-group were a 40% decrease in mean PAP and a 49% decrease in TPR (follow-up period; 17.4±9.3 months). The 2-year survival rate in the Drug-group was 82.0%, and the 2-year survival rate, occurrence of right heart failure, and re-vascularization rate in the PEA-group were 97.4%, 2.6%, and 2.8%, and those in the PTPA-group were 98.5%, 2.9%, and 2.9%, respectively. CONCLUSION: The patients who underwent interventional therapies had better results than those treated only with drugs. The availability of both of these operative and catheter-based interventional therapies leads us to expect the dawn of a new era of therapeutic strategies for CTEPH.
format Online
Article
Text
id pubmed-3984177
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-39841772014-04-15 A New Era of Therapeutic Strategies for Chronic Thromboembolic Pulmonary Hypertension by Two Different Interventional Therapies; Pulmonary Endarterectomy and Percutaneous Transluminal Pulmonary Angioplasty Inami, Takumi Kataoka, Masaharu Ando, Motomi Fukuda, Keiichi Yoshino, Hideaki Satoh, Toru PLoS One Research Article BACKGROUND: Pulmonary endarterectomy (PEA) is established for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH). Recently, percutaneous transluminal pulmonary angioplasty (PTPA) has been added for peripheral-type CTEPH, whose lesions exist in segmental, subsegmental, and more distal pulmonary arteries. A shift in clinical practice of interventional therapies occurred in 2009 (first mainly PEA, later PTPA). We examined the latest clinical outcomes of patients with CTEPH. METHODS AND RESULTS: This study retrospectively included 136 patients with CTEPH. Twenty-nine were treated only with drug (Drug-group), and the other 107 underwent interventional therapies (Interventions-group) (39 underwent PEA [PEA-group] and 68 underwent PTPA [PTPA-group]). Total 213 PTPA sessions (failures, 0%; mortality rate, 1.47%) was performed in the PTPA-group (complications: reperfusion pulmonary edema, 7.0%; hemosputum or hemoptysis, 5.6%; vessel dissection, 2.3%; wiring perforation, 0.9%). Although baseline hemodynamic parameters were significantly more severe in the Interventions-group, the outcome after the diagnosis was much better in the Interventions-group than in the Drug-group (98% vs. 64% 5-year survival, p<0.0001). Hemodynamic improvement in the PEA-group was a 46% decrease in mean pulmonary arterial pressure (PAP) and a 49% decrease in total pulmonary resistance (TPR) (follow-up period; 74.7±32.3 months), while those in the PTPA-group were a 40% decrease in mean PAP and a 49% decrease in TPR (follow-up period; 17.4±9.3 months). The 2-year survival rate in the Drug-group was 82.0%, and the 2-year survival rate, occurrence of right heart failure, and re-vascularization rate in the PEA-group were 97.4%, 2.6%, and 2.8%, and those in the PTPA-group were 98.5%, 2.9%, and 2.9%, respectively. CONCLUSION: The patients who underwent interventional therapies had better results than those treated only with drugs. The availability of both of these operative and catheter-based interventional therapies leads us to expect the dawn of a new era of therapeutic strategies for CTEPH. Public Library of Science 2014-04-11 /pmc/articles/PMC3984177/ /pubmed/24728482 http://dx.doi.org/10.1371/journal.pone.0094587 Text en © 2014 Inami et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Inami, Takumi
Kataoka, Masaharu
Ando, Motomi
Fukuda, Keiichi
Yoshino, Hideaki
Satoh, Toru
A New Era of Therapeutic Strategies for Chronic Thromboembolic Pulmonary Hypertension by Two Different Interventional Therapies; Pulmonary Endarterectomy and Percutaneous Transluminal Pulmonary Angioplasty
title A New Era of Therapeutic Strategies for Chronic Thromboembolic Pulmonary Hypertension by Two Different Interventional Therapies; Pulmonary Endarterectomy and Percutaneous Transluminal Pulmonary Angioplasty
title_full A New Era of Therapeutic Strategies for Chronic Thromboembolic Pulmonary Hypertension by Two Different Interventional Therapies; Pulmonary Endarterectomy and Percutaneous Transluminal Pulmonary Angioplasty
title_fullStr A New Era of Therapeutic Strategies for Chronic Thromboembolic Pulmonary Hypertension by Two Different Interventional Therapies; Pulmonary Endarterectomy and Percutaneous Transluminal Pulmonary Angioplasty
title_full_unstemmed A New Era of Therapeutic Strategies for Chronic Thromboembolic Pulmonary Hypertension by Two Different Interventional Therapies; Pulmonary Endarterectomy and Percutaneous Transluminal Pulmonary Angioplasty
title_short A New Era of Therapeutic Strategies for Chronic Thromboembolic Pulmonary Hypertension by Two Different Interventional Therapies; Pulmonary Endarterectomy and Percutaneous Transluminal Pulmonary Angioplasty
title_sort new era of therapeutic strategies for chronic thromboembolic pulmonary hypertension by two different interventional therapies; pulmonary endarterectomy and percutaneous transluminal pulmonary angioplasty
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984177/
https://www.ncbi.nlm.nih.gov/pubmed/24728482
http://dx.doi.org/10.1371/journal.pone.0094587
work_keys_str_mv AT inamitakumi aneweraoftherapeuticstrategiesforchronicthromboembolicpulmonaryhypertensionbytwodifferentinterventionaltherapiespulmonaryendarterectomyandpercutaneoustransluminalpulmonaryangioplasty
AT kataokamasaharu aneweraoftherapeuticstrategiesforchronicthromboembolicpulmonaryhypertensionbytwodifferentinterventionaltherapiespulmonaryendarterectomyandpercutaneoustransluminalpulmonaryangioplasty
AT andomotomi aneweraoftherapeuticstrategiesforchronicthromboembolicpulmonaryhypertensionbytwodifferentinterventionaltherapiespulmonaryendarterectomyandpercutaneoustransluminalpulmonaryangioplasty
AT fukudakeiichi aneweraoftherapeuticstrategiesforchronicthromboembolicpulmonaryhypertensionbytwodifferentinterventionaltherapiespulmonaryendarterectomyandpercutaneoustransluminalpulmonaryangioplasty
AT yoshinohideaki aneweraoftherapeuticstrategiesforchronicthromboembolicpulmonaryhypertensionbytwodifferentinterventionaltherapiespulmonaryendarterectomyandpercutaneoustransluminalpulmonaryangioplasty
AT satohtoru aneweraoftherapeuticstrategiesforchronicthromboembolicpulmonaryhypertensionbytwodifferentinterventionaltherapiespulmonaryendarterectomyandpercutaneoustransluminalpulmonaryangioplasty
AT inamitakumi neweraoftherapeuticstrategiesforchronicthromboembolicpulmonaryhypertensionbytwodifferentinterventionaltherapiespulmonaryendarterectomyandpercutaneoustransluminalpulmonaryangioplasty
AT kataokamasaharu neweraoftherapeuticstrategiesforchronicthromboembolicpulmonaryhypertensionbytwodifferentinterventionaltherapiespulmonaryendarterectomyandpercutaneoustransluminalpulmonaryangioplasty
AT andomotomi neweraoftherapeuticstrategiesforchronicthromboembolicpulmonaryhypertensionbytwodifferentinterventionaltherapiespulmonaryendarterectomyandpercutaneoustransluminalpulmonaryangioplasty
AT fukudakeiichi neweraoftherapeuticstrategiesforchronicthromboembolicpulmonaryhypertensionbytwodifferentinterventionaltherapiespulmonaryendarterectomyandpercutaneoustransluminalpulmonaryangioplasty
AT yoshinohideaki neweraoftherapeuticstrategiesforchronicthromboembolicpulmonaryhypertensionbytwodifferentinterventionaltherapiespulmonaryendarterectomyandpercutaneoustransluminalpulmonaryangioplasty
AT satohtoru neweraoftherapeuticstrategiesforchronicthromboembolicpulmonaryhypertensionbytwodifferentinterventionaltherapiespulmonaryendarterectomyandpercutaneoustransluminalpulmonaryangioplasty